latest news releases from the newsroom
Airvana Wins 2006 3G CDMA Industry Achievement Award
CHELMSFORD, Mass. and HONG KONG, Dec. 7, 2006 (PRIME NEWSWIRE) -- Airvana, Inc. (www.airvana.com), an innovator and leader in mobile broadband infrastructure based on 3G wireless packet data technology, today announced that it won the CDMA Development Group's (CDG) 2006 3G CDMA Industry Achievement Award for Network Technology Innovation. Winners were announced yesterday evening during the Mobile Entertainment Forum's (MEF) wireless industry reception in Hong Kong. Several companies and individuals were recognized for excellence in deploying advanced 3G CDMA networks, products, and services.
Golden Patriot Corp.
Golden Patriot, Corp.: Uranium Samples Sent for Testing On Past Producing Uranium Prospect
LAKE SUCCESS, N.Y., Dec. 7, 2006 (PRIME NEWSWIRE) -- Golden Patriot, Corp. ("Golden Patriot") (OTCBB:GPTC) (Frankfurt:GPU) is extremely pleased to announce that the samples taken from Phase I of the successfully completed drill program on the past producing Lucky Boy Uranium Prospect in Arizona have now been shipped from Jacob Laboratories to IPL Labs for final testing. Over 650 samples were prepared averaging more than 6 pounds per sample for over 4,000 pounds of samples that were separated, bagged and tagged for shipment to IPL Labs. Assaying should be completed shortly.
Golden Ocean Group Limited
Golden Ocean Group Ltd. -- Issuance of Options
HAMILTON, Bermuda, Dec. 7, 2006 (PRIME NEWSWIRE) -- In connection with the employment of Geir Karlsen as CFO in Golden Ocean Management AS, he has been granted 500,000 share options. The options are granted at a strike price which has been set at NOK 8.30 which is in accordance with the approved share option scheme.
Basilea Pharmaceutica Ltd
Basilea to Co-Promote Ceftobiprole
BASEL, Switzerland, Dec. 7, 2006 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that it has exercised its co-promotion option on ceftobiprole, its investigational anti-MRSA cephalosporin antibiotic, in North America and major European countries with Johnson & Johnson's affiliate Cilag GmbH International. Basilea will participate in the anticipated launch and promotion of ceftobiprole in these markets.
Axium Technologies, Inc.
Axium Technologies Completes Entry Into the Public Market as Part of Its Continuing Growth Strategy
PASADENA, Calif., Dec. 6, 2006 (PRIME NEWSWIRE) -- Axium Technologies, Inc. (Pink Sheets:AXGI) is pleased to announce its entry into the public market, as it begins trading under the symbol AXGI.PK. Axium Technologies, Inc. ("Axium or the "Company") (www.axiumtech.net) is a provider of stand alone products and integrated systems technology directed at the commercial electronic security and surveillance market. This market size in which Axium participates is $26 billion of sales per annum growing at a minimum of 8% per year. Originally formed in 2002 as World Wide Eyes, Inc., the Company's growth and diversity into new products and markets dictated a change not only in the structure of the company, but also in a name more befitting its vision. To address these needs, World Wide Eyes Inc. changed its name to Axium Technologies, Inc. in 2004. Axium presently has 14 employees, divided between its executive and sales office in Pasadena California and its research and development office in South Korea.